H. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine

Similar documents
Myeloma update ASH 2014

Disclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon

Proteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes

Disclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson

Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

ClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

CME Information LEARNING OBJECTIVES

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

Progress in Multiple Myeloma

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):

Multiple Myeloma: ASH 2008

Multiple Myeloma Brian Berryman, M.D. March 8 th, 2014

Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant

How to Integrate the New Drugs into the Management of Multiple Myeloma

Multiple Myeloma Updates 2007

Multiple Myeloma: Induction, Consolidation and Maintenance Therapy

Elotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)

Dana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3

Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors

Smoldering Myeloma: Leave them alone!

Novel Combination Therapies for Untreated Multiple Myeloma

Eltanexor (KPT-8602), a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

POMALYST (pomalidomide) for Previously Treated Multiple Myeloma

Daratumumab: Mechanism of Action

Study Rationale. Reference: Chanan-Khan, A., et al., ASH 2010, Abstract#1962. Reference: Whiteman, K., et al, AACR, 2009, Abstract#2799

City of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1

DARA Monotherapy Studies

ClinicalTrials.gov Identifier: NCT

Disclosures for Palumbo Antonio, MD

A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma

Dana-Farber Cancer Institute, Boston, MA, USA; 2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3

ASCO Analyst & Investor Webcast. June 1, 2018

Future Strategies For Refractory Myeloma. Marc S. Raab

Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma

COMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France

Management of Multiple

Millennium Pharmaceuticals, Inc., Cambridge, MA; 11 Dana-Farber Cancer Institute, Boston, MA

Treatment of elderly multiple myeloma patients

Methods: Studies included in the analysis

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )

Horizon Scanning Centre November Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436

MSN, ANP-BC, AOCNP1*, R.

Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain

Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy

Oncology Highlights ASCO 2011 MULTIPLE MYELOMA

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial

Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma

Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone

Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study

CREDIT DESIGNATION STATEMENT

IMiDs (Immunomodulatory drugs) and Multiple Myeloma

Michel Delforge Belgium. New treatment options for multiple myeloma

Idelalisib in the Treatment of Chronic Lymphocytic Leukemia

Conflict of Interest Disclosure Form

Ninlaro. (ixazomib) New Product Slideshow

La lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara

Updates in Multiple Myeloma: 12 months in 10 minutes

POMALIDOMIDE AND LOW DOSE DEXAMETHASONE

Living Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern

Daratumumab: Mechanism of Action

Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

This was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.

TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE

Unmet Medical Needs and Latest Multiple Myeloma Treatment

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment

Is autologous stem cell transplant the best consolidation after initial therapy?

Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes

New drugs in multiple myeloma role of carfilzomib and pomalidomide

ClinicalTrials.gov Identifier: NCT

Current management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School

Daratumumab: Mechanism of Action

Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD

Managing Newly Diagnosed Multiple Myeloma

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA

Update on Multiple Myeloma Treatment

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Myeloma and renal failure Future directions. Karthik Ramasamy

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW

Scottish Medicines Consortium

Multiple Myeloma: Diagnosis and Primary Treatment

At Fox Chase Cancer Centre during study participation

This was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.

from 20 February 2014

SCIENTIFIC DISCUSSION

BCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Phase 1, Multicenter, Open-label, Doseescalation,

Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions

Recent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma.

Multiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009

Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma

Making Sense of Myeloma Treatment Advances

Practical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors

BR is an established treatment regimen for CLL in the front-line and R/R settings


Transcription:

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas G Martin III, Melissa Alsina, Kenneth H. Shain, Hearn J. Cho, Jeffrey L. Wolf, Anuj Mahindra, Ajai Chari, Daniel M. Sullivan, Lisa A. Nardelli, Kenneth Lau, Xiuhua Zhao, Hui-Yi Lin, and Sundar Jagannath H. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine

Background Pomalidomide-dexamethasone results in an overall response rate of 33% and median PFS of 4.2 months in patients with prior lenalidomide and bortezomib 1 Alkylating agents (melphalan, cyclophosphamide) represent standard of care therapy for patients with multiple myeloma with the latter being associated with less myelosuppression In addition, a combination of lenalidomide and continuous cyclophosphamide resulted in an ORR of 50% in lenalidomide refractory patients 2 Larocca et al. combined continuous pomalidomide with oral cyclophosphamide 3. MTD: pomalidomide 2.5 mg PO daily, cyclophosphamide 50 mg PO QOD, Prednisone 50 mg PO QOD x 6 cycles followed by pomalidomide/pred maintenance ORR 51%, median PFS 10.4 months 1-Richardson PG et al. Blood 2014;123(12):1826-32. 2- Van de Donk N et al. BJH 2009; 148:335. 3-Larocca A et al. Blood 2013;122(16):2799-806.

Dose level Background Phase I study: Arm A Dose escalation of oral weekly cyclophosphamide in combination with standard pomalidomide dexamethasone Cyclophosphamide -1 300 mg PO D1,8 1 300 mg PO D1,8,15 2 400 mg PO D,1,8,15 3 500 mg PO D1,8,15 Recommended phase II dose Pom 4 mg Cy 400mg Dex 40mg Baz R et al. Blood (ASH), Nov 2012; 120: 4062

1:1 Randomization Study Design: Treatment Plan Arm B (28 days cycle) Pomalidomide 4mg PO D1-21/28 days Dexamethasone 40*mg PO D1,8,15,22 Arm C (28 days cycle) Pomalidomide 4mg PO D1-21/28 days Cyclophosphamide 400 mg PO D1,8,15 Dexamethasone 40* mg PO D1,8,15,22 Arm D: Cross Over for PD at discretion of patient and treating physician * Dexamethasone 20 mg was given if patient was older than 75 years or unable to tolerate 40 mg of dexamethasone ** Aspirin 81-325 mg daily as prophylactic antithrombotic treatment unless contraindicated. If aspirin is contraindicated, patients will receive another form of antithrombotic therapy (low molecular weight heparin or therapeutic anticoagulation with warfarin)

Randomized Phase II trial Primary endpoint: Compare the overall response rate (PR or better) of arm B versus C (IMWG response criteria) Secondary endpoints: Progression free survival (PFS) OS (overall survival) Safety NCI CTC version 4.0 ORR for arm D (IMWG)

Statistical Considerations Intent to treat (ITT) analysis: all patients randomized to treatment were analyzed according to the treatment to which they were randomized A sample size of 70 patients achieves 78% power to detect the group difference of 30% using the two-sided Fisher s exact test assuming the response rate of arm B is 30% and arm C 60% with a significant level of 10%

Eligibility Key eligibility criteria At least 2 prior therapies and must be lenalidomide refractory (PD while receiving or within 60 days of discontinuing lenalidomide) Measurable disease (Serum M spike 0.5 g/dl, or Urine M spike 200 mg/24h, or iflc>100mg/l and abn ratio) ECOG performance status 2 Serum creatinine < 3mg/dL ANC 1000/mm3 (GCSF allowed during screening) Platelet count 50,000/mm3 (or 30,000/mm3 if greater than 50% BMPC) Washout period 2 weeks from cycle 1 day 1

Patient Characteristics Arm B (N=36) Arm C (N=34) P value Age, years, median (range) 64 (50-78) 65 (47-80) 0.7 Male, n (%) 23 (64) 18 (53) 0.5 Number of prior therapies, median (range) Bortezomib refractory, n (%) Carfilzomib refractory, n (%) Prior high-dose therapy, n (%) Prior alkylating agent, n (%) 4 (2-12) 28 (78) 16 (44) 27 (75) 32 (89) 4 (2-9) 24 (71) 13 (38) 28 (82) 32 (94) 0.5 0.4 0.6 0.7 1.0 B2-microglobulin, median (range) 3.2 (1.6-10) 3.6 (1.5-13.9) 0.5 Serum creatinine, median (range) 1 (0.5-2.3) 0.9 (0.6-2.1) 0.6 High-risk cytogenetics, n (%) Deletion 17p, n (%) t(4;14), n (%) Trisomy or tetrasomy 1q, n (%) 8 (22) 6 (16) 4 (11) 18 (50) 7 (21) 5 (15) 3 (9) 9 (26) 1.0 0.6 0.6 0.1

Results: IMWG response rate P=0.1 90 80 P=0.03 79.4 70 60 61.1 64.7 50 40 30 38.9 ORR ( PR) CBR ( MR) VGPR 20 10 13.8 11.8 0 Arm B (Pom Dex) Arm C (Pom Cy Dex)

Proportion Results: PFS 1.0 0.8 Arm B C 0.6 0.4 0.2 Log-rank p = 0.1078 0.0 0 3 6 9 12 15 18 21 24 27 Progression-free survival (months) Arm B C N 36 34 Event 30 (83%) 26 (76%) Censored 6 (17%) 8 (24%) Median (95% CI) 4.4(2.3, 6.0) 9.5(4.6, 13.6)

Proportion Results: OS 1.0 0.8 Arm B+D C 0.6 0.4 0.2 Log-rank p = 0.1308 0.0 0 3 6 9 12 15 18 21 24 27 Overall survival (months) Arm B+D C N 36 34 Event 20 (56%) 13 (38%) Censored 16 (44%) 21 (62%) Median (95% CI) 16.8(9.3, NA) NA(13.0, NA)

Results: Gr3/4 AE in >5% of patients Lymphopenia Other infections Fatigue Febrile Neutropenia Pneumonia (incl pneumonitis) Thrombocytopenia Anemia Neutropenia (at least possibly related) 0 5 5 8 8 11 11 11 11 11 13 15 17 0 10 20 30 40 50 60 Percent of patients * Includes 1 patient with grade 5 pneumonia. * 22 33 49 Arm C (Pom Cy Dex) Arm B (Pom Dex)

Results: All cause, all grade nonhematologic AE in >15% of patients Fever Weakness (muscle) Edema Lung Infection URI Fatigue Diarrhea Nausea Constipation Hyperglycemia Tremors 0 10 20 30 40 Percent of patients Arm C (Pom Cy Dex) Arm B (Pom Dex)

Cross Over: Arm D As of 11/2014, 15 patients (out of 30 eligible) crossed over from Arm B to arm D (addition of oral weekly cyclophosphamide to the tolerated dose of pomalidomide dexamethasone). Safety: the percent of patients with grade 3 / 4 at least possibly related adverse events is as follows: Neutropenia 33%, Febrile neutropenia 13%, Anemia 6%, pneumonia / pneumonitis 6%, fatigue 6%, fever 6%. IMWG responses: ORR ( PR) was 13% with 2 PR, 2 MR, 7 SD, 3 PD, 1 NE. 14/15 have progressed with a median PFS of 3 months (range 1-9 months).

Pomalidomide combinations N Dose / Schedule ORR PFS Pomalidomide Dex 113 Pom 4 mg D1-21 Dex 40 mg weekly + Clarithromycin 1 114 Pom 4 mg D1-21 Dex 40 mg weekly Clarithromycin 500 mg BID + Bortezomib 2 20 Bort: 1.3 mg/m2 D1,4,8,11 Pom: 4 mg D1-14 Dex: 20mg D1,2,4,5,8,9,11,12 + Carfilzomib 3 67 Carfil: 20/27 mg/m2 D1,2,8,9,15,16 Pom: 4 mg D1-21 Dex: 40 mg weekly + Liposomal Doxorubicin 4 29 PLD: 5 mg/m2 IVD1,4,8,11 Pom: 4 mg D1-21 Dex: 40 mg weekly + Cyclophosphamide 5 55 Cy: 50 mg PO QOD Pom 2.5 mg 28/28 Pred 50 mg QOD 33% 4.7 61.4% 8.1 75% N/A 64% 12 34.5% N/A 51% 10.4 +/- Cyclophosphamide 6 70 Pom 4 mg D1-21 Dex 40 mg weekly +/- Cy 400 mg PO D1,8,15 1- Mark et al. ASH 2013, abstract 1955; 2-Richardson et al. Blood 2014;123(12):1826-32; 3-Shah et al. ASH 2013 abstract 690; 4- Berenson et al. ASH 2013 abstract 3218; 5- Larocca et al. Blood 2013 Oct 17;122(16):2799-806 6- Baz et ASH 2014 39% 65% 4.4 9.5

Conclusions and future directions As compared to pomalidomide dexamethasone, Pom Cy Dex results in A superior response rate (ORR 65% versus 39%) An improvement in progression free and overall survival of borderline significance. Pom Cy Dex was well tolerated with possible increased hematologic adverse events which are manageable. This regimen compares favorably with other pomalidomide based regimens in terms of efficacy, toxicities and cost. The addition of cyclophosphamide for patients progressing on pomalidomide and dexamethasone results in minimal clinical benefits. Baseline levels of Cereblon, Ikaros and Aiolos will be correlated with clinical benefits.

Acknowledgments Patients and their families All research and clinical personnel including investigators, research nurses, trials coordinators, regulatory specialists Moffitt Clinical Research Network Moffitt biostatistic team This study was funded by Celgene